22 results
8-K
EX-3.1
MCRB
Seres Therapeutics Inc
2 Jan 24
Amendments to Articles of Incorporation or Bylaws
4:05pm
, conflict of interest, confidentiality, stock ownership and trading and other policies and guidelines of the Corporation applicable to directors … that there may be a conflict of interest or position on any significant issue between the Corporation and Indemnitee in the conduct of the defense
PRE 14A
MCRB
Seres Therapeutics Inc
14 Apr 23
Preliminary proxy
4:30pm
or Alpine's work in 2022 raised a conflict of interest.
The Compensation and Talent Committee recognizes the very competitive market for executive
8-K
EX-10.3
k1cnb55 xf
30 Jun 22
Entry into a Material Definitive Agreement
8:02am
8-K
EX-10.1
wbp6kqkz9l uwt1ef
20 May 21
Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business Development
8:30am
8-K
EX-3.1
pi1dge899
7 Dec 20
Termination of a Material Definitive Agreement
7:03am
8-K
EX-10.1
uquz10 u7r
4 Nov 19
Entry into a Material Definitive Agreement
5:01pm